Fanyi Zeng, of the Institute of Medical Genetics at Shanghai Jiao Tong University, is to present her recently published paper on iPS cells producing viable mice at the 2009 World Stem Cell Summit.
Zeng will participate on the science panel 'Human Embryonic Stem Cells versus Induced Pluripotent Cells'.
Bernard Siegel, co-chair of the World Stem Cell Summit, said: 'We congratulate Zeng and her colleague Qi Zhou on their achievement, which clearly demonstrates the versatility of reprogrammed cells in mice.
'Their research has broad applications and will place us further along the path to understanding the earliest stage of development and the root causes of disease.
'The work of Zeng is of keen interest to the global stem cell community and the general public.' The 2009 World Stem Cell Summit will take place on 21-23 September at the Baltimore Convention Center, Baltimore, Maryland, US.
Presented by the Genetics Policy Institute (GPI), the Summit is hosted by Johns Hopkins University, the University System of Maryland, University of Maryland-Baltimore, Maryland Department of Business and Economic Development, Maryland Technology Development Corporation and Maryland Stem Cell Research Fund.
The comprehensive, multi-track programme covers all areas of stem cell science (embryonic, adult and iPS), disease progress reports, drug discovery, tissue engineering, scaffolds, bioreactors and nanotechnology.
Panels cover commercialisation, funding, economic development, federal agencies' perspectives, biobanking and ethics.
